There are 2789 resources available
840P - Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Presenter: Yuan-Kai Shi
Session: ePoster Display
879P - Adaptive radiotherapy in head and neck cancer: A prospective dosimetric and volumetric study
Presenter: Apurva Pandey
Session: ePoster Display
880P - Systematic literature review (SLR) of randomized controlled trials in patients (pts) with newly diagnosed locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) ineligible for surgery
Presenter: Karthik Ramakrishnan
Session: ePoster Display
881P - Impact of neck dissection in N2-3 oropharyngeal squamous-cell carcinomas treated with definitive chemo-radiotherapy: An observational real-life study
Presenter: Guillaume Klausner
Session: ePoster Display
882P - Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer
Presenter: Lu Li
Session: ePoster Display
883P - Preliminary study of a new antibody marker anti-EBV BNLF2b in screening population in high-incidence areas of nasopharyngeal carcinoma
Presenter: Mingfang Ji
Session: ePoster Display
Resources:
Abstract
884P - Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Presenter: Susanne Flach
Session: ePoster Display
885P - Molecular response to induction chemotherapy and its correlation with treatment outcome in head and neck cancer patients by means of NMR-based metabolomics
Presenter: Lukasz Boguszewicz
Session: ePoster Display
886P - Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients
Presenter: Kirsty Taylor
Session: ePoster Display
887P - Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Sung-Bae Kim
Session: ePoster Display